How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

3,582 results for

Eosinophilia-Myalgia Syndrome

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

2. Eosinophilia-Myalgia Syndrome

Eosinophilia-Myalgia Syndrome Eosinophilia-Myalgia Syndrome Toggle navigation Brain Head & Neck Chest Endocrine Abdomen Musculoskeletal Skin Infectious Disease Hematology & Oncology Cohorts Diagnostics Emergency Findings Procedures Prevention & Management Pharmacy Resuscitation Trauma Emergency Procedures Ultrasound Cardiovascular Emergencies Lung Emergencies Infectious Disease Pediatrics Neurologic Emergencies Skin Exposure Miscellaneous Abuse Cancer Administration 4 Eosinophilia-Myalgia (...) Syndrome Eosinophilia-Myalgia Syndrome Aka: Eosinophilia-Myalgia Syndrome From Related Chapters II. Associated Conditions III. Pathophysiology Linked to L-Tryptophan usage IV. Symptoms Myalgias (Uniformly present) Rapid onset with persistent pain Severe and incapacitating pain Associated with muscle spasms (esp. calves, ) Associated with perceived weakness Exacerbated by movement s (73%) Non-productive cough with (59%) (27%) or Hypesthesia (e.g. Burning sensation) V. Signs Rash (60%) (59%) Cutaneous

2018 FP Notebook

3. 34m with fever, headache and myalgias

sanitation worker with an acute onset febrile syndrome with headaches, myalgias, cholestatic liver injury, thrombocytopenia, and an AKI with microscopic hematuria. So really a multiorgan inflammatory state, in which the clinical scenario still seems most compelling and most pressing to look for infection. And I would go back to the infection category being broken down even more thoroughly by bacteria, viral, etc, and sort of force myself at this point to commit to what organisms I’m most worried about (...) 34m with fever, headache and myalgias Core IM Hoofbeats: 34M with Fever, Headache and Myalgias – Clinical Correlations Search Core IM Hoofbeats: 34M with Fever, Headache and Myalgias January 16, 2019 15 min read Podcast: | Subscribe: | By Shira Sachs MD, Stephanie Sherman MD, Cindy Fang MD and John Hwang MD || Audio Editing by Richard Chen || Graphic by Amy Ou MD Time Stamps Player three has entered the game! [0:15] Case presentation, part 1 [1:20] First impressions [3:24] Rethinking another

2019 Clinical Correlations

4. Myalgia and chronic fatigue syndrome following immunization: macrophagic myofasciitis and animal studies support linkage to aluminum adjuvant persistency and diffusion in the immune system. (PubMed)

Myalgia and chronic fatigue syndrome following immunization: macrophagic myofasciitis and animal studies support linkage to aluminum adjuvant persistency and diffusion in the immune system. Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) is a multifactorial and poorly undersood disabling disease. We present epidemiological, clinical and experimental evidence that ME/CFS constitutes a major type of adverse effect of vaccines, especially those containing poorly degradable particulate (...) and distinctive pattern of cerebral glucose hypometabolism. Deltoid muscle biopsy performed to investigate myalgia typically yields macrophagic myofasciitis (MMF), a histological biomarker assessing longstanding persistency of aluminum agglomerates within innate immune cells at site of previous immunization. MMF is seemingly linked to altered mineral particle detoxification by the xeno/autophagy machinery. Comparing toxicology of different forms of aluminum and different types of exposure is misleading

2019 Autoimmunity reviews

5. Imatinib-Associated Tumor Lysis Syndrome in a Patient With Myeloid Neoplasm With Eosinophilia and PDGFRA Rearrangement: A Case Report and Review of the Literature (Full text)

Imatinib-Associated Tumor Lysis Syndrome in a Patient With Myeloid Neoplasm With Eosinophilia and PDGFRA Rearrangement: A Case Report and Review of the Literature 30241197 2019 03 04 2378-9506 4 2018 Sep Journal of global oncology J Glob Oncol Imatinib-Associated Tumor Lysis Syndrome in a Patient With Myeloid Neoplasm With Eosinophilia and PDGFRA Rearrangement: A Case Report and Review of the Literature. 1-4 10.1200/JGO.2016.007716 Socola Francisco F All authors: University of Arkansas

2017 Journal of global oncology PubMed

6. Assessment of eosinophilia

Assessment of eosinophilia Assessment of eosinophilia - Differential diagnosis of symptoms | BMJ Best Practice You'll need a subscription to access all of BMJ Best Practice Search  Assessment of eosinophilia Last reviewed: February 2019 Last updated: August 2018 Summary Eosinophilia is defined as an increase in the peripheral blood eosinophil count. The upper limit of normal is usually taken as about 0.6 × 10⁹/L (600/microlitre), but it is lower (about 0.4 × 10⁹/L [400/microlitre]) if people (...) with minor allergies are excluded. There is no ethnic variation in the normal eosinophil count and no physiological cause of an increased count. Bain BJ. Blood cells: a practical guide. 5th ed. Oxford: Wiley-Blackwell; 2015. Causes of eosinophilia The most common causes of eosinophilia depend on socioeconomic and geographical factors. In the developing world the most common cause is parasitic infection (and parasitic infections result in the greatest number of cases worldwide), whereas in the developed

2018 BMJ Best Practice

7. Aggressive treatment in paediatric or young patients with drug-induced hypersensitivity syndrome (DiHS)/drug reaction with eosinophilia and systemic symptoms (DRESS) is associated with future development of type III polyglandular autoimmune syndrome (Full text)

Aggressive treatment in paediatric or young patients with drug-induced hypersensitivity syndrome (DiHS)/drug reaction with eosinophilia and systemic symptoms (DRESS) is associated with future development of type III polyglandular autoimmune syndrome We experienced a 6-year-old case of drug-induced hypersensitivity syndrome (DiHS)/drug reaction with eosinophilia and systemic symptoms (DRESS) with subsequent development autoimmune thyroiditis (Hashimoto's thyroiditis), type 1 diabetes (...) with antithyroglobulin, thyroid peroxidase, insulinoma-associated antigen and anti-insulin antibodies at 4 months, alopecia at 7 months, vitiligo, uveitis due to Vogt-Koyanagi-Harada disease at 8 months after clinical resolution of the DiHS/DRESS. He was diagnosed as type III polyglandular autoimmune syndrome (PASIII) after DiHS/DRESS. Prompted by this case, we sought to determine which triggering factors were responsible for later development of PASIII in previously published cases with autoimmune sequelae

2018 BMJ case reports PubMed

8. Drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome caused by first-line antituberculous drugs: two case reports and a review of the literature. (PubMed)

Drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome caused by first-line antituberculous drugs: two case reports and a review of the literature. Patients suffering from drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome caused by first-line antituberculous drugs often need to be re-treated rapidly. Patch tests prior to the re-introduction of antituberculosis drugs are rarely performed.We aim to highlight those drugs most often involved in DRESS from (...) antituberculosis drugs, illustrate the potential value of patch tests to identify these culprit(s), and provide insights in how to rapidly re-treat these patients.A detailed description of the work-up of two illustrative patients, together with a literature review of similar cases, is provided.All first-line antituberculosis drugs may cause DRESS syndrome, but rifampicin and isoniazid are most frequently involved. Patch tests can be performed sooner than usually advised in the context of DRESS syndrome

2019 Contact Dermatitis

9. Prophylactic Gabapentin for Taxane-Induced Arthralgia and Myalgia Syndrome in Breast Cancer Patients Undergoing Adjuvant Chemotherapy

Prophylactic Gabapentin for Taxane-Induced Arthralgia and Myalgia Syndrome in Breast Cancer Patients Undergoing Adjuvant Chemotherapy Prophylactic Gabapentin for Taxane-Induced Arthralgia and Myalgia Syndrome in Breast Cancer Patients Undergoing Adjuvant Chemotherapy - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You (...) have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Prophylactic Gabapentin for Taxane-Induced Arthralgia and Myalgia Syndrome in Breast Cancer Patients Undergoing Adjuvant Chemotherapy The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before

2018 Clinical Trials

10. Protracted febrile myalgia syndrome treated with pulse of corticosteroids. (PubMed)

Protracted febrile myalgia syndrome treated with pulse of corticosteroids. This study describes our 5-year experience treating protracted febrile myalgia syndrome (PFMS) with pulsed doses of corticosteroids.Eight patients with PFMS who received pulse corticosteroid therapy were identified from the electronic database of a tertiary pediatric medical center (2011-2016). Their clinical and laboratory data were collected. Differences in continuous variables between hospital admission and discharge

2017 Seminars in arthritis and rheumatism

11. Eosinophilia-Myalgia Syndrome (Overview)

Eosinophilia-Myalgia Syndrome (Overview) Dermatologic Manifestations of Eosinophilia-Myalgia Syndrome: Background, Pathophysiology, Etiology Edition: No Results No Results Please confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. https://profreg.medscape.com/px/getpracticeprofile.do?method=getProfessionalProfile&urlCache=aHR0cHM6Ly9lbWVkaWNpbmUubWVkc2NhcGUuY29tL2FydGljbGUvMTA2NjgxMS1vdmVydmlldw (...) == processing > Dermatologic Manifestations of Eosinophilia-Myalgia Syndrome Updated: Jun 21, 2018 Author: Robert A Schwartz, MD, MPH; Chief Editor: William D James, MD Share Email Print Feedback Close Sections Sections Dermatologic Manifestations of Eosinophilia-Myalgia Syndrome Overview Background Eosinophilia-myalgia syndrome (EMS) was first recognized in 1989 in New Mexico in 3 patients who had an illness with a unique array of symptoms, including peripheral blood eosinophilia and severe myalgias. All 3

2014 eMedicine.com

12. Eosinophilia-Myalgia Syndrome (Overview)

Eosinophilia-Myalgia Syndrome (Overview) Eosinophilia-Myalgia Syndrome: Practice Essentials, Pathophysiology, Epidemiology Edition: No Results No Results Please confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. https://profreg.medscape.com/px/getpracticeprofile.do?method=getProfessionalProfile&urlCache=aHR0cHM6Ly9lbWVkaWNpbmUubWVkc2NhcGUuY29tL2FydGljbGUvMzI5NjE0LW92ZXJ2aWV3 processing (...) > Eosinophilia-Myalgia Syndrome Updated: Dec 01, 2017 Author: William E Monaco, MD; Chief Editor: Herbert S Diamond, MD Share Email Print Feedback Close Sections Sections Eosinophilia-Myalgia Syndrome Overview Practice Essentials Eosinophilia-myalgia syndrome (EMS) was first identified in 1989, when approximately 1500 patients developed subacute onset of myalgias and peripheral eosinophilia.They then went on to have chronic muscle, fascia, nerve, and skin involvement. The Centers for Disease Control

2014 eMedicine.com

13. Eosinophilia-Myalgia Syndrome (Diagnosis)

Eosinophilia-Myalgia Syndrome (Diagnosis) Dermatologic Manifestations of Eosinophilia-Myalgia Syndrome: Background, Pathophysiology, Etiology Edition: No Results No Results Please confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. https://profreg.medscape.com/px/getpracticeprofile.do?method=getProfessionalProfile&urlCache=aHR0cHM6Ly9lbWVkaWNpbmUubWVkc2NhcGUuY29tL2FydGljbGUvMTA2NjgxMS1vdmVydmlldw (...) == processing > Dermatologic Manifestations of Eosinophilia-Myalgia Syndrome Updated: Jun 21, 2018 Author: Robert A Schwartz, MD, MPH; Chief Editor: William D James, MD Share Email Print Feedback Close Sections Sections Dermatologic Manifestations of Eosinophilia-Myalgia Syndrome Overview Background Eosinophilia-myalgia syndrome (EMS) was first recognized in 1989 in New Mexico in 3 patients who had an illness with a unique array of symptoms, including peripheral blood eosinophilia and severe myalgias. All 3

2014 eMedicine.com

14. Eosinophilia-Myalgia Syndrome (Diagnosis)

Eosinophilia-Myalgia Syndrome (Diagnosis) Eosinophilia-Myalgia Syndrome: Practice Essentials, Pathophysiology, Epidemiology Edition: No Results No Results Please confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. https://profreg.medscape.com/px/getpracticeprofile.do?method=getProfessionalProfile&urlCache=aHR0cHM6Ly9lbWVkaWNpbmUubWVkc2NhcGUuY29tL2FydGljbGUvMzI5NjE0LW92ZXJ2aWV3 processing (...) > Eosinophilia-Myalgia Syndrome Updated: Dec 01, 2017 Author: William E Monaco, MD; Chief Editor: Herbert S Diamond, MD Share Email Print Feedback Close Sections Sections Eosinophilia-Myalgia Syndrome Overview Practice Essentials Eosinophilia-myalgia syndrome (EMS) was first identified in 1989, when approximately 1500 patients developed subacute onset of myalgias and peripheral eosinophilia.They then went on to have chronic muscle, fascia, nerve, and skin involvement. The Centers for Disease Control

2014 eMedicine.com

15. Eosinophilia-Myalgia Syndrome (Treatment)

Eosinophilia-Myalgia Syndrome (Treatment) Dermatologic Manifestations of Eosinophilia-Myalgia Syndrome Treatment & Management: Medical Care, Consultations, Complications Edition: No Results No Results Please confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. https://profreg.medscape.com/px/getpracticeprofile.do?method=getProfessionalProfile&urlCache (...) =aHR0cHM6Ly9lbWVkaWNpbmUubWVkc2NhcGUuY29tL2FydGljbGUvMTA2NjgxMS10cmVhdG1lbnQ= processing > Dermatologic Manifestations of Eosinophilia-Myalgia Syndrome Treatment & Management Updated: Jun 21, 2018 Author: Robert A Schwartz, MD, MPH; Chief Editor: William D James, MD Share Email Print Feedback Close Sections Sections Dermatologic Manifestations of Eosinophilia-Myalgia Syndrome Treatment Medical Care The most important component of eosinophilia-myalgia syndrome (EMS) treatment is to discontinue the use of any product containing L-tryptophan. The mainstay of pharmacologic

2014 eMedicine.com

16. Eosinophilia-Myalgia Syndrome (Treatment)

Eosinophilia-Myalgia Syndrome (Treatment) Eosinophilia-Myalgia Syndrome Treatment & Management: Medical Care, Consultations, Diet Edition: No Results No Results Please confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. https://profreg.medscape.com/px/getpracticeprofile.do?method=getProfessionalProfile&urlCache=aHR0cHM6Ly9lbWVkaWNpbmUubWVkc2NhcGUuY29tL2FydGljbGUvMzI5NjE0LXRyZWF0bWVudA== processing (...) > Eosinophilia-Myalgia Syndrome Treatment & Management Updated: Dec 01, 2017 Author: William E Monaco, MD; Chief Editor: Herbert S Diamond, MD Share Email Print Feedback Close Sections Sections Eosinophilia-Myalgia Syndrome Treatment Medical Care The first and most important step is to discontinue the L-tryptophan or other possible offending agent(s). No medication has been shown to alter the course of the disease, but high-dose steroids (eg, equivalent of prednisone 60 mg/day) may be helpful in acutely ill

2014 eMedicine.com

17. Eosinophilia-Myalgia Syndrome (Follow-up)

Eosinophilia-Myalgia Syndrome (Follow-up) Dermatologic Manifestations of Eosinophilia-Myalgia Syndrome Treatment & Management: Medical Care, Consultations, Complications Edition: No Results No Results Please confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. https://profreg.medscape.com/px/getpracticeprofile.do?method=getProfessionalProfile&urlCache (...) =aHR0cHM6Ly9lbWVkaWNpbmUubWVkc2NhcGUuY29tL2FydGljbGUvMTA2NjgxMS10cmVhdG1lbnQ= processing > Dermatologic Manifestations of Eosinophilia-Myalgia Syndrome Treatment & Management Updated: Jun 21, 2018 Author: Robert A Schwartz, MD, MPH; Chief Editor: William D James, MD Share Email Print Feedback Close Sections Sections Dermatologic Manifestations of Eosinophilia-Myalgia Syndrome Treatment Medical Care The most important component of eosinophilia-myalgia syndrome (EMS) treatment is to discontinue the use of any product containing L-tryptophan. The mainstay of pharmacologic

2014 eMedicine.com

18. Eosinophilia-Myalgia Syndrome (Follow-up)

Eosinophilia-Myalgia Syndrome (Follow-up) Eosinophilia-Myalgia Syndrome Follow-up: Further Outpatient Care, Further Inpatient Care, Inpatient & Outpatient Medications Edition: No Results No Results Please confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. https://profreg.medscape.com/px/getpracticeprofile.do?method=getProfessionalProfile&urlCache (...) =aHR0cHM6Ly9lbWVkaWNpbmUubWVkc2NhcGUuY29tL2FydGljbGUvMzI5NjE0LWZvbGxvd3Vw processing > Eosinophilia-Myalgia Syndrome Follow-up Updated: Dec 01, 2017 Author: William E Monaco, MD; Chief Editor: Herbert S Diamond, MD Share Email Print Feedback Close Sections Sections Eosinophilia-Myalgia Syndrome Follow-up Further Outpatient Care Because symptoms of EMS tend to be prolonged, sometimes persisting for years, intermittent treatment with muscle relaxants and analgesics may be required. Next: Further Inpatient Care Patients who are acutely ill with EMS may require

2014 eMedicine.com

19. C-Reactive Protein and Procalcitonin in Case Reports of Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) Syndrome. (Full text)

C-Reactive Protein and Procalcitonin in Case Reports of Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) Syndrome. The spectrum of inflammatory marker response in DRESS (drug reaction with eosinophilia and systemic symptoms) syndrome has not been systematically characterized.An epidemiological biomarker study of C-reactive protein (CRP) and procalcitonin (PCT) values in patients with DRESS syndrome reported at 2 regional pharmacovigilance centers in Switzerland or published (...) and hepatic enzyme measurements.Evaluating CRP and PCT values might be of use in helping physicians to distinguish between cases of DRESS syndrome with and without concurrent infection or other causes of inflammation. Further prospective investigation is required to define the use of these inflammatory markers in the management of DRESS.© 2018 S. Karger AG, Basel.

2018 International Archives of Allergy and Immunology PubMed

20. Drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome: Case report of severe multiorgan involvement to perindopril/amlodipine combination antihypertensive (Full text)

Drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome: Case report of severe multiorgan involvement to perindopril/amlodipine combination antihypertensive 29387775 2019 02 26 2352-5126 4 2 2018 Mar JAAD case reports JAAD Case Rep Drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome: Case report of severe multiorgan involvement to perindopril/amlodipine combination antihypertensive. 170-174 10.1016/j.jdcr.2017.10.007 Chan Linda L Concord Repatriation General (...) symptoms RegiSCAR, Registry of Severe Cutaneous Adverse Reactions amlodipine drug reaction drug reaction with eosinophilia and systemic symptoms syndrome perindopril renal impairment 2018 2 2 6 0 2018 2 2 6 0 2018 2 2 6 1 epublish 29387775 10.1016/j.jdcr.2017.10.007 S2352-5126(17)30259-X PMC5789762 Australas J Dermatol. 2014 Feb;55(1):15-23 23866082 J Eur Acad Dermatol Venereol. 2015 Nov;29(11):2199-205 26354734 Arch Dermatol. 2010 Dec;146(12):1373-9 20713773 Int J Dermatol. 2015;54(5):537-42 24738653

2018 JAAD Case Reports PubMed

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>